J F Lyons

Summary

Affiliation: Cork University Hospital
Country: Ireland

Publications

  1. ncbi Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies
    John Lyons
    Curr Opin Investig Drugs 4:1442-50. 2003
  2. ncbi Discovery of a novel Raf kinase inhibitor
    J F Lyons
    Onyx Pharmaceuticals, 3031 Research Drive, Richmond, California 94806, USA
    Endocr Relat Cancer 8:219-25. 2001
  3. ncbi Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies
    Jean Pierre J Issa
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 103:1635-40. 2004
  4. ncbi Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
    Neil Thompson
    Astex Technology Ltd, 436 Cambridge Science Park, Milton Rd, Cambridge CB4 0QA, UK
    Curr Opin Pharmacol 5:350-6. 2005

Detail Information

Publications4

  1. ncbi Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies
    John Lyons
    Curr Opin Investig Drugs 4:1442-50. 2003
    ..DAC has activity in several hematological diseases, especially myelodysplastic syndrome, chronic myelogenous leukemia and acute myeloid leukemia. Clinical and preclinical advances are presented in this review...
  2. ncbi Discovery of a novel Raf kinase inhibitor
    J F Lyons
    Onyx Pharmaceuticals, 3031 Research Drive, Richmond, California 94806, USA
    Endocr Relat Cancer 8:219-25. 2001
    ..Finally, a small molecule drug discovery program based on inhibition of Raf kinase activity is outlined and the initial pre-clinical development process of the Raf kinase inhibitor BAY 43-9006 is discussed...
  3. ncbi Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies
    Jean Pierre J Issa
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 103:1635-40. 2004
    ..There was no correlation between P15 methylation at baseline or after therapy and response to decitabine. We conclude that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses...
  4. ncbi Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
    Neil Thompson
    Astex Technology Ltd, 436 Cambridge Science Park, Milton Rd, Cambridge CB4 0QA, UK
    Curr Opin Pharmacol 5:350-6. 2005
    ..Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise...